On January 5, 2022 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, reported that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022 (Press release, Mannkind, JAN 5, 2022, View Source [SID1234598231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at View Source The webcast replay may be accessed at the same location for 14 days.